Notably, Yoshida et al. reported that anti-PD-1 antibodies reduced Tregs infiltration in osteosarcoma, correlating with tumor growth delay and prolonged survival (Yoshida et al., 2020). Here, PDCD1 is linked to osteosarcoma.